Acrivon adds immunology pillar, reports Q3 2026 results and ACR-2316 data aheadNov 16Quarterly updateACR-2316Acrivon Therapeutics
Regeneron-linked TOP2201 posts results; NeoSTOP-IT terminated, DEUTERON completedNov 5Weekly roundup, 7 itemsafliberceptALN-CIDEBUpdated
Regeneron registers Phase 3 LINKER-AL1 trial of linvoseltamab for AL amyloidosisOct 30Weekly roundup, 6 itemscemiplimab-rwlcdupilumabUpdated
Alnylam posts Q3 2026 results, widens nucresiran trial, advances Huntington's programOct 29Quarterly updateAlnylam Pharmaceuticalsnucresiran
Pfizer registers four studies: elranatamab, berobenatide, tilrekimig, and completed etrasimod trialOct 23Weekly roundup, 14 itemsabrocitinibatirmociclibUpdated
AbbVie's CANASA label update and ABBV-253 trial recruitment lead busy week of registry changesOct 16Weekly roundup, 9 itemsABBV-1042ABBV-253Updated
Novartis clinicaltrials.gov records update across scleroderma, urticaria and SMA studiesOct 16Weekly roundup, 7 itemsianalumabNovartis
Pfizer registers real-world observational study of marstacimab in hemophilia A and B patientsOct 9Weekly roundup, 8 itemsabrocitinibcyclophosphamide
Regeneron and Sanofi expand antibody collaboration to four new assetsOct 6Quarterly updateRegeneron PharmaceuticalsSanofi
Regeneron's EYLEA HD posts Phase 3b safety results; dupilumab keloid study completesSep 18Weekly roundup, 2 itemsafliberceptdupilumab
Pfizer posts MET097 obesity results; registers new Phase 3 obesity and dermatitis trialsAug 28Weekly roundup, 6 itemsberobenatidePF-08154225
Innovent registers Phase 3 trial comparing IBI3027 to dupilumab in atopic dermatitisAug 10Trial updatedupilumabInnovent Biologics
Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial missesJul 30Quarterly updatecemdisiranfianlimab